Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  ISIS Pharmaceuticals, Inc.    ISIS

 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2016 238 M
EBIT 2016 -154 M
Net income 2016 -187 M
Finance 2016 134 M
Yield 2016 -
Sales 2017 287 M
EBIT 2017 -154 M
Net income 2017 -179 M
Finance 2017 155 M
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales2016 13,8x
EV / Sales2017 11,4x
Capitalization 3 428 M
More Financials
Company
Ionis Pharmaceuticals, Inc. engages in the development and commercialization of antisense drug discovery.It operates through two segments: Drug Discovery & Development Operations and Akcea.The Drug Discovery & Development Operations segment provides drugs to treat a variety of health conditions,... 
More about the company
Surperformance© ratings of ISIS Pharmaceuticals, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on ISIS PHARMACEUTICALS, INC.
07/19 IONIS PHARMACEUTICALS : Licenses First Oral Antisense Drug Acting Locally in the..
07/17 STATE STREET : Increases Stake in Ionis Pharmaceuticals Inc.
07/12 IONIS PHARMACEUTICALS : Announces Publication in Nature Biotechnology of a Novel..
07/07 IONIS PHARMACEUTICALS : Reports Positive Clinical Data on IONIS-TTR Rx at the XV..
06/29 IONIS PHARMACEUTICALS : Akcea Therapeutics Announces Launch of IN-FOCUS, a Resea..
06/27 IONIS PHARMACEUTICALS : Akcea Announces Publication of Positive Volanesorsen Cli..
06/22 IONIS PHARMACEUTICALS : to Host R&D Day
06/16 IONIS PHARMACEUTICALS : Novel imaging model helps reveal new therapeutic target ..
06/08DJJudge Sides With Gilead in Drug-Patent Dispute -- WSJ
06/07DJJudge Sides With Gilead Against Merck in Case Over Hepatitis C Drug Patents
More news
Sector news : Biotechnology & Medical Research - NEC
12:45a GILEAD SCIENCES : cuts 2016 sales forecast, cites hepatitis C drugs
07/25DJGILEAD SCIENCES : Sales of Hepatitis C Drugs Fall 19% -- 2nd Update
07/25DJCELGENE : Drug Misses Secondary Endpoint in One of Its Lymphoma Trials
07/25DJGILEAD SCIENCES : Sales of Hepatitis C Drugs Fall 19% -- 3rd Update
07/25DJGILEAD SCIENCES : Sales of Hepatitis C Drugs Fall 19% -- Update
More sector news : Biotechnology & Medical Research - NEC
4-Traders Strategies on ISIS PHARMACEUTICALS, INC. 
2014A resistance as obstacle
More Strategies
News from SeekingAlpha
2015 Game Plan For The Week - Cramer's Mad Money (12/18/15)
2015 PREMARKET BIOTECH DIGEST : Portola's Milestone, Shkreli Resigns, BioMarin DMD Dr..
2015 Isis Pharma has had enough, name changed to Ionis Pharmaceuticals
2015 Bear Afoot? No Recession Needed For A Possible Sighting
2015 PREMARKET BIOTECH DIGEST : Gilead's Upside, Shire-Baxalta Deal, ARIAD Lowers Gui..
Advertisement
Chart ISIS PHARMACEUTICALS, INC.
Duration : Period :
ISIS Pharmaceuticals, Inc. Technical Analysis Chart | ISIS | US4643301090 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus HOLD
Number of Analysts 12
Average target price 32,4 $
Spread / Average Target 14%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Stanley T. Crooke Chairman, President & Chief Executive Officer
B. Lynne Parshall Chief Operating Officer & Director
Elizabeth L. Hougen Chief Financial Officer & SVP-Finance
C. Frank Bennett Senior Vice President-Antisense Research
Joseph H. Wender Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ISIS PHARMACEUTICALS, ..-6.12%3 428
INCYTE CORPORATION-20.30%16 216
CELLTRION, INC.--.--%10 681
LONZA GROUP AG11.40%9 730
QUINTILES TRANSNATIONA..7.89%8 865
ALKERMES PLC-36.86%7 576
More Results